This recombinant monoclonal antibody is developed as a research-grade biosimilar to teprotumumab, targeting the insulin-like growth factor 1 receptor (IGF1R). IGF1R is a transmembrane tyrosine kinase receptor that plays a critical role in cell growth, proliferation, differentiation, and survival through activation of downstream PI3K/AKT and MAPK signaling pathways. Aberrant IGF1R signaling is implicated in various cancers where it promotes tumor growth and metastasis, as well as in thyroid eye disease where IGF1R overexpression on orbital fibroblasts contributes to tissue remodeling and inflammation.
Teprotumumab is a full human monoclonal antibody that inhibits IGF1R signaling and represents the first FDA-approved treatment for thyroid eye disease. This biosimilar antibody provides researchers with a valuable tool for investigating IGF1R-mediated cellular processes, exploring the mechanisms underlying thyroid-associated ophthalmopathy, and studying IGF1R as a therapeutic target in oncology and autoimmune conditions. It enables comprehensive examination of IGF1R biology and antibody-based therapeutic strategies in relevant disease models.
Email: support@cusabio.com
Distributors Worldwide